Sponsor:
Tango Therapeutics, Inc.
Code:
NCT05887492
Conditions
Non Small Cell Lung Cancer
Solid Tumors, Adult
Lung Cancer
Lung Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TNG260
Pembrolizumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-09. This information was provided to ClinicalTrials.gov by Tango Therapeutics, Inc. on 2025-04-11.